Company profile
9 Meters Biopharma, Inc.
OTC: NMTRQ · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 26
v0.1 · 5/100 weight · pillars only
↑ listing tenure, balance-sheet leverage · ↓ return on equity, market scale
Methodology →Revenue TTM
—
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$43.8M
Employees
10
as of 2026-09-03
Market cap
$1.4k
as of 2026-09-03
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$43.8M-$43.8M2022
Operating income-$42.0M-$42.0M2022
Total assets$33.1M$33.1M2022
Liabilities$30.7M$30.7M2022
Equity$2.4M$2.4M2022
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is 9 Meters Biopharma, Inc.’s financial profile?
9 Meters Biopharma, Inc. earned -$43.8M in FY2022 net income.
Peers · Healthcare
Evelo Biosciences, Inc.——Juva Life Inc.——Assure Holdings Corp.——MSP Recovery, Inc.——PsyBio Therapeutics Corp——FusionPharm, Inc.——Neighbors
Wake →Key facts
CEOPeter H. R. Green
SectorHealthcare
IndustryBiotechnology
HeadquartersRaleigh, NC
ExchangeOTC: NMTRQ
Employees10
IPO date2016-07-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.